Krystal Biotech Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
All right, everyone. I'd like to thank everyone for joining us today at the Goldman Sachs Global Healthcare Conference, and we're so pleased to be joined by Krish Krishnan from Krystal Biotech to give us a good update on where things are, where things headed into, there's really kind of, no pun intended, pivotal year for the company.
Questions & Answers
So Krish, let's start at a big picture level. Why don't we walk through Krystal's herpes simplex virus or HSV gene therapy platform, including a rundown of both pipeline candidates and ongoing clinical studies.
Sure. First, thanks for having me. Thanks for having the company. So Krystal's HSV-1 is a DNA virus with many favorable properties as a delivery vector for therapeutic genes, including other exogenous generic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
